kidney disease

October 30, 2014

NIH grant spurs diabetic nephropathy research

Diabetic nephropathy, or kidney disease caused by diabetes, is a major source of morbidity and mortality. In the United States, more than 30 percent of patients receiving either dialytic therapy or renal transplantation have end stage renal disease as a result of diabetic nephropathy.

By Kathy Whitney

August 21, 2014

Major grant spurs deeper look into ‘good cholesterol’

In some cases, HDL, the “good cholesterol,” may not function properly and may actually accelerate atherosclerosis.

By Bill Snyder

August 7, 2014

Study tracks new end-stage renal disease therapy

Researchers in Vanderbilt’s Division of Nephrology conducted a Phase 3 clinical trial to test the safety and efficacy of a new drug to treat patients with end-stage renal disease.

By Kathy Whitney

July 10, 2014

Molecular ‘chat’ holds kidney fibrosis clues

A novel molecular “conversation” regulates kidney fibrosis – the final result of end-stage chronic kidney disease – suggesting new treatment options for this currently irreversible process.

By Leigh MacMillan

June 26, 2014

VU study shows common diabetes drug can slow chronic kidney disease progression

Vanderbilt investigators have demonstrated in two studies that metformin-based treatments delay the onset and progression of chronic kidney disease (CKD) compared with other treatments for diabetes.

By Kathy Whitney

May 29, 2014

New center dedicated to kidney disease

Kidney disease is the eighth most common cause of death in the United States and affects more than 20 million people, yet many people don’t know they have kidney disease because it often develops very slowly and with minimal symptoms. For this reason, kidney disease is often referred to as a silent killer.